Revive Therapeutics Ltd. announced that Tessio Rebello, Ph.D., will join the Company as a clinical advisor for the Company. Dr. Rebello previously held the position of Vice President of Clinical Development at VIRxSYS Corporation where he led the successful launch of anti-sense, gene therapy (VRX496), Phase 2 clinical trial for the treatment of HIV-infected patients who fail to respond to conventional drug therapies and two other Phase 2 clinical trials involving the same drug.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.025 CAD | 0.00% | 0.00% | -16.67% |
1st Jan change | Capi. | |
---|---|---|
-16.67% | 7.66M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- RVV Stock
- News Revive Therapeutics Ltd.
- Revive Therapeutics Appoints Tessio Rebello as Clinical Advisor